Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R3R01 for albuminuria in diabetic kidney disease
2024-511484-29-00Phase 2Authorised
- Sponsor
- River 3 Renal Corp
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in diabetic glomerulosclerosis comparing R3R01 with Placebo (2 arms). Primary endpoint: Urinary albumin-to-creatinine ratio. Planned start Oct 2024; status: authorised.
02
Drugs
R3R01
03
Conditions
diabetic glomerulosclerosis
Beyond the preview
Go deeper on 2024-511484-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511484-29-00.